BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$8.11 USD
-0.04 (-0.49%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BCRX 8.11 -0.04(-0.49%)
Will BCRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BCRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCRX
Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect?
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates
BCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
Other News for BCRX
BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO? (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks
BioCryst completes negotiations with pCPA for PrORLADEYO
Caligan Partners LP Bolsters Portfolio with Significant Stake in Liquidia Corp
BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
Tracking Baker Brothers Portfolio - Q2 2024 Update